WO2016023140A1 - 一种用于细胞三维培养的基质支架及其构建方法和应用 - Google Patents
一种用于细胞三维培养的基质支架及其构建方法和应用 Download PDFInfo
- Publication number
- WO2016023140A1 WO2016023140A1 PCT/CN2014/000771 CN2014000771W WO2016023140A1 WO 2016023140 A1 WO2016023140 A1 WO 2016023140A1 CN 2014000771 W CN2014000771 W CN 2014000771W WO 2016023140 A1 WO2016023140 A1 WO 2016023140A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- silk fibroin
- solution
- prepared
- scaffold
- culture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
Definitions
- the invention relates to a matrix scaffold for three-dimensional culture of cells and a construction method and application thereof.
- the scaffold acts as a substrate for replacing the extracellular matrix or tissues and organs, and is further useful for in vitro differentiation and expansion of cells, tissue organ remodeling, and tumor drug screening.
- Cells are our common research objects, and the cytological level of our research is basically carried out in a two-dimensional culture state, because cells in the body (whether adherent or non-adherently grown cells) are in a certain matrix. Growth under the support, so the two-dimensional culture environment in vitro can not truly reflect the internal environment of the cells.
- three-dimensional culture technology has gradually become a research hotspot in the field of cell culture. It uses various materials and methods to make cells grow in a three-dimensional space, and its growth is closer to the in vivo growth pattern of cells, forming a tissue structure similar to the body. Play its physiological functions.
- the commonly used three-dimensional culture techniques mainly include dynamic culture and static culture.
- Dynamic culture mainly includes spinner flask culture and rotary cell culture system. Although this kind of culture technique makes the cells function better through mechanical stimulation, it is difficult to promote the use due to higher requirements.
- Static culture is to directly inoculate cells on a three-dimensional vector and culture without applying any physical methods.
- pre-set matrix culture provides a scaffold environment similar to cell growth in vivo, and is relatively simple to operate, but is critically dependent on matrix material selection.
- matrices are derived from animal gels such as collagen I, gelatin or extracted extracellular matrices, but animal gels are expensive and contain many uncertain components.
- CN101445971A, CN103418029A discloses a biomimetic extracellular matrix silk fibroin/chitosan composite nanofiber made of silk fibroin and chitosan, which provides the best biomimetic physiological environment for cell growth and tissue regeneration.
- the disadvantage is that the silk fibroin solution prepared by the invention has relatively low stability and is difficult to be industrially applied.
- CN102010601A, CN101624472A and CN101624473A disclose the preparation of a hepatocyte-specific macroporous microcarrier scaffold material by silk fibroin and galactosylated chitosan under the action of a crosslinking agent, which is suitable for large-scale cultivation of hepatocytes.
- the disadvantage is that the manufacturing process is cumbersome (chitosan is crosslinked by glycosylation and then filtered by a mesh sieve), and the prepared scaffold material is a large-aperture stent, and the application range is limited.
- CN102942660A discloses a natural bio-crosslinked nano-composite three-dimensional gel scaffold, which is formed by in-situ radical polymerization of acrylamide monomer, inorganic nanoclay, biopolymer and biocrosslinker genipin dissolved in water. It can be used for medical transplantation, drug release and cell culture.
- the disadvantage is that the main material used is that acrylamide is easily decomposed by high heat to release an irritating gas; and the acrylic acid converted into an acid-base environment has a strong toxic effect on cells.
- CN103418029A discloses a silk fibroin/chitosan composite porous scaffold made of silk fibroin and chitosan.
- the disadvantage is that the composite has poor stability and is not suitable for industrial production and wide application.
- Chinese patent CN102952279A discloses a method for preparing a hydrogel by reacting a methyl vinyl ether/maleic acid copolymer with a crosslinking agent and its use in tumor tissue culture, but since the matrigel contains a large amount of cell growth factors (such as Epidermal growth factor, fibroblast growth factor and tissue plasminogen activator), the uncertainty of the role of these cytokines in cultured cells.
- cell growth factors such as Epidermal growth factor, fibroblast growth factor and tissue plasminogen activator
- the present invention provides a matrix scaffold material for three-dimensional culture of cells, which is similar to a scaffold of a cell body environment, and can be used for in vitro expansion, tissue and organ of difficult-to-cultivate cells. Reconstruction and screening of tumor drugs.
- a matrix scaffold for three-dimensional culture of cells which is prepared by cross-linking reaction of silk fibroin-like substance, chitosan and cross-linking agent, characterized in that the silk fibroin-like substance is composed of silkworm pupa or silk
- the silk fibroin powder is obtained by degumming, dissolving, dialysis and drying, and the silk fibroin powder is obtained by the following method:
- step (2) dialysis of the dissolved silk fibroin solution of step (1) with a dialysis bag having a molecular weight cutoff of 3500 Da to prepare a dialyzed silk fibroin solution;
- the dialysis bag containing the dialyzed silk fibroin solution prepared in the step (2) is placed in a polyethylene glycol 6000 powder for concentration, and the obtained concentrate is centrifuged, and the supernatant is taken, thereby obtaining the above-mentioned Silk fibroin-like substances.
- cross-linking agent is preferably 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC) and N-hydroxyl Succinimide (NHS).
- the above-mentioned matrix scaffold for three-dimensional culture of cells wherein the silk fibroin-like substance, shell
- the reaction product obtained after the crosslinking reaction of the polysaccharide and the crosslinking agent is subjected to gradient freezing to obtain the matrix scaffold, and the gradient freezing process is as follows -
- reaction product is pre-frozen in a refrigerator at 20 ° C for 12 to 48 h, then frozen in a -80 ° C low-temperature refrigerator for 12 to 48 h, and finally freeze-dried in a freeze dryer for 24 to 72 h.
- the preliminary three-dimensional scaffold material obtained in the step (1) is immersed in a solution of anhydrous methanol and 10% sodium hydroxide (volume ratio 1: 1) for 12 to 48 hours, rinsed with deionized water, and then placed. After drying in a freeze dryer for 24 to 72 hours, it is taken out.
- the matrix scaffold for cell three-dimensional culture described above is characterized by being obtained by a method comprising the following steps -
- step 2) adding the dried silk fibroin prepared in the step 1) to the boiled 50% calcium chloride solution, stirring and dissolving, cooling and filtering;
- the dissolved silk fibroin solution prepared in the step 4) is cooled to normal temperature, it is poured into a dialysis bag having a molecular weight cutoff of 3500 Da for 2-4 days to remove small molecular substances in the silk fibroin solution;
- the dialyzed silk fibroin solution prepared in the step 5) is stored in a dialysis bag, placed in a polyethylene glycol 6000 powder, dried and concentrated, and the liquid is collected, and the supernatant is obtained by centrifugation;
- step 3 The cross-linked reaction product of step 2) was pre-frozen in a -20 ⁇ refrigerator for 24 h, then frozen in a low-temperature refrigerator at _80 ° C for 24 h, and finally freeze-dried in a freeze dryer for 48 h to obtain a preliminary system.
- Three-dimensional scaffold material
- step 4) Immerse the scaffold material prepared in step 3) in a solution of anhydrous methanol and 10% sodium hydroxide (1:1 by volume) After 24 h, it was washed 3 times with deionized water, and then dried in a freeze dryer for 48 h, and then taken out, and the matrix scaffold for three-dimensional culture of cells was obtained.
- the above-mentioned matrix scaffold for three-dimensional culture of cells wherein the concentration of the silk fibroin-like substance solution is 1% to 5%, and the concentration of the chitosan solution is 1% to 5%.
- a matrix scaffold as described above, characterized in that it is used for in vitro expansion, tissue organ remodeling or drug screening of cells.
- the use described above is for stem cell culture, tumor microenvironment construction, tumor drug screening or tissue organ reconstruction engineering.
- the embryonic tissue is isolated for in vitro differentiation of myocytes, tumor tissue-associated tumor-associated macrophages (TAMs) or tumor-associated fibroblasts (TAFs).
- TAMs tumor tissue-associated tumor-associated macrophages
- TAFs tumor-associated fibroblasts
- a method for in vitro expansion of a cell comprising using the matrix scaffold described above as a scaffold material for three-dimensional culture of cells.
- the matrix framework of the present invention the silk fibroin substance obtained by the method is cross-linked with chitosan and a cross-linking agent, and the silk fibroin-type substance/chitosan solution and the cross-linking agent are adjusted. Concentrations and ratios to obtain three-dimensional matrix scaffolds of different pore sizes and/or conformations.
- the present invention also provides a method for preparing a matrix scaffold for cell three-dimensional culture as described above.
- the method includes the following steps -
- the prepared silk fibroin liquid is stored in a dialysis bag, placed in a polyethylene glycol 6000 powder, dried and concentrated, and the liquid is collected, and the supernatant is centrifuged.
- the silk fibroin solution prepared in the step 1 is mixed with the chitosan solution prepared in the step 2.
- the use of the matrix scaffold of the present invention is preferably applied to in vitro differentiation of embryonic tissue-derived myocytes, tumor tissue-associated tumor-associated macrophages (TAMs), and tumor-associated fibroblasts (TAFs) in vitro expansion.
- TAMs tumor tissue-associated tumor-associated macrophages
- TAFs tumor-associated fibroblasts
- the invention adopts silkworm cocoon shell or silk as raw material, and obtains natural silk fibroin substance through a specific extraction process, and uses the non-toxic cross-linking agent 1 as a raw material, and natural chitosan (CS) raw material.
- Ethyl_3_[3-dimethylaminopropyl]carbodiimide (EDC) and N-hydroxysuccinimide (NHS) are cross-linked, and the conformation of the prepared three-dimensional matrix scaffold is close to the spatial conformation of the cell body.
- EDC dimethylaminopropyl]carbodiimide
- NHS N-hydroxysuccinimide
- the silk fibroin-like substance and chitosan prepared from silkworm pupa or silk of the invention have been proved to have good biocompatibility and non-toxicity, and have simple operation, low cost, etc. compared with animal gel. advantage.
- the three-dimensional matrix framework prepared by the present invention is suitable for both adherent cells and non-adherent cells. In this three-dimensional environment, cells exclude the contact inhibition effect in two-dimensional culture.
- the results of in vitro studies in this system can more objectively reflect the life activities of the physiological state of the cells and improve the reliability of the research results.
- three-dimensional matrix scaffolds with different pore sizes and conformations can be obtained. Different pore sizes can be selected according to the structural characteristics of the cells in the culture target cells.
- a three-dimensional culture system with different matrix conformations, which is satisfied with the primary culture of cells of different tissue sources, should be The scope of use and its wide range can be applied to in vitro expansion, tissue organ reconstruction and tumor drug screening of difficult cultured cell bodies.
- the conformation of the cell three-dimensional culture matrix material of the present invention is similar to the fiber tissue conformation in the microenvironment of the cell body, and the primary isolated cells can adapt to the growth environment in vitro as soon as possible, based on the cell biology in the three-dimensional (3D) culture process.
- the learning behavior is close to the body, reducing the error of the experimental results in vitro and in vivo, and has significant social benefits.
- Figure 1 Image of a matrix framework material prepared in Example 1 of the present invention under light microscopy and scanning electron microscopy.
- FIG. 3 Proliferation (cell cycle) of primary myoblasts in a three-dimensional matrix culture prepared in Example 1 of the present invention.
- Figure 4. Tumor-associated macrophages (TAMs) in a three-dimensional matrix culture prepared in Example 1.
- Figure 6 Comparison of the effect of the matrix scaffold material of the present invention on the degradability of the scaffold material prepared by the existing silk fibroin.
- Figure 7. The scaffold material of the present invention and the scaffold material prepared by the existing silk fibroin. Comparison of the effects of proliferative capacity
- Figure 1 Three-dimensional matrix framework material after freeze-drying, optical microscope (Olympus CX21, Japan) observed by adjusting the concentration and ratio of silk fibroin/chitosan solution and cross-linking agent to obtain three-dimensional with different pore sizes Matrix scaffold, Figure 1A-B (magnification X 400); Scanning electron microscope (Philippines XL20, Netherlands) Electron microscopy of the matrix structure (see Figure 1C).
- Fig. 2 It can be seen from the figure that the myotube formation rate of myoblasts in 3D and 2D cultures gradually increases with the prolongation of culture time, while the myotube formation rate of myoblasts cultured from 3D cultures is from the sixth of culture. The day begins until the 12th day and maintains a platform period. Myoblast myotube formation rates in 3D and 2D cultures were 17% and 33% on day 12, respectively.
- Figure 4 It can be seen from the figure that the 0D values of 3D and 2D cultured TAMs increased significantly from the 4th day of culture, while the 0D values of 3D cultured TAMs started from the 6th day of culture until the 15th day. Maintain a higher platform period. 3D and 2D cultured The OD value of the TAMs was 0.63 and 0.43 on the 15th day.
- Fig. 5 it can be seen from the figure that the 0D values of TAMs cultured in 3D and 2D increased significantly from the second day of culture, and the 0D values of 2D cultured TAMs began to decrease on the 10th day; and TAMs cultured in 3D The 0D value continued to rise until the 15th day before it began to decline.
- the degradation rate of the three-dimensional scaffold prepared by using the silk fibroin solution prepared by the prior art is as high as 21. 2%, and the silk fibroin prepared by the method of the present invention is prepared.
- the degradation rate of the three-dimensional scaffolds prepared by the material was not increased significantly with the lapse of time, only 9.4% after 7W.
- the silk fibroin solution prepared by the prior art does not maintain the original physical and chemical properties of the silk fibroin, resulting in the degradation rate of the prepared three-dimensional scaffold with the silk fibroin solution.
- the time is increased and the time is increased.
- the substrate for three-dimensional culture of the cells provided by the invention is cross-linked by using the silk fibroin/chitosan solution of the invention and a cross-linking agent, by adjusting the silk fibroin/chitosan solution and cross-linking
- concentration and ratio of the agent, three-dimensional matrix scaffolds with different pore sizes and conformations were obtained, and the three-dimensional matrix with different pore sizes was arranged according to the characteristics of the tissue structure of the cells in the culture target, and the attached cells were provided for the cells after inoculation, and the two-dimensional culture was excluded.
- the contact inhibition effect causes the cells to grow in a state similar to the in vivo microenvironment.
- Example 1 Matrix framework material for three-dimensional culture of cells and construction method thereof
- the prepared silk fibroin liquid is stored in a dialysis bag, placed in a polyethylene glycol 6000 powder, dried and concentrated, and the liquid is collected, centrifuged at 3500 r/min for 15 min, and the supernatant is taken and placed at 4 ° C. It can be stored in the refrigerator for one week.
- the silk fibroin concentration obtained in this example is about 2% to 3%.
- the silk fibroin solution prepared in the step 1 is mixed with the chitosan solution prepared in the step 2.
- the former contains the three-dimensional matrix of silk fibroin prepared in Example 1 (referred to as 3D culture, the same below), and the latter is a common culture plate (referred to as 2D culture). , the same below).
- Myotube fusion rate is the ratio of the number of nuclei in the myotube to the number of all nuclei per unit of view.
- the rate of myotube formation reflects the differentiation state of myoblasts.
- a high rate of myotube formation indicates that a large number of cells have withdrawn from the cell cycle and entered a differentiated state. The experiment was repeated three times for statistical analysis.
- the experimental results show that the three-dimensional matrix provides a similar environment-like scaffold for myoblasts, which is beneficial to the proliferation of myoblasts, thus slowing the induction of differentiation of myoblasts.
- Example 1 As in the above 2) (1), a 24-well culture plate of the experimental group and the control group was separately established, and the former contained the three-dimensional matrix of silk fibroin prepared in Example 1, which was an ordinary culture plate.
- the experimental results showed that the synthesis phase (S phase) cells of the myoblasts in the 2D medium at 1 day, 3 days and 6 days were 33%, 28% and 23%, respectively, while in the 3D medium, 1 day, 3 The S phase cells at day and 6 days were 32%, 39%, and 41%, respectively (see Figure 3).
- the experimental results show that most of the myoblasts cultured in 2D exit the cell cycle and differentiate into terminal cells. In the 3D cultured cells, the proportion of cells in the synthesis phase is higher, and most of the cells are in In the proliferation phase, it is suggested that 3D medium can be used for in vitro expansion of difficult-to-culture cells.
- Example 3 Culture and expansion of tumor mesenchymal cells extracted from tumor tissues in a three-dimensional matrix of silk fibroin
- TMAs tumor-associated macrophages
- Fresh colon cancer tissue was cut into 2 mm pieces, digested with a PBS containing 0.3% collagenase at 37 ° C to form a cell suspension, and the cell suspension was filtered through a 70 ra stainless steel mesh, centrifuged, and washed with PBS.
- TAFs tumor-associated fibroblasts
- Example 2 In the same manner as in 2) (1) of the above Example 2, a 24-well culture plate of the experimental group and the control group was separately established, and the former contained the three-dimensional matrix of silk fibroin prepared in Example 1, which was an ordinary culture plate.
- TAMs and TAFs isolated and identified from the above tumor tissues were inoculated into two 24-well culture plates according to 5 ⁇ 10 OVml, and cultured in DMEM containing 10% calf serum for 1 day, and then changed to contain 5% small. Bovine serum was cultured in DMEM.
- Example 4 Comparative test: Comparison of the degradation properties of the substrate scaffolds prepared by the method of the present invention and the silk fibroin prepared according to the prior art (CN103418029A)
- Example 2 2) according to the steps of Example 1 of the present invention 1) to obtain a 3% silk fibroin solution;
- the crosslinked scaffolds A and B were prepared by using the silk fibroin liquids prepared in 1) and 2), respectively, in the same manner as in the step 3) of the first embodiment.
- the A scaffold is a matrix scaffold material prepared from silk fibroin prepared according to the prior art
- the B scaffold is a matrix scaffold material prepared by using the silk fibroin-based material obtained by the method of the present invention as a raw material.
- the artificial body fluid (SBF solution) is used as an in vitro degradation environment, and the degradation temperature is 37 °C.
- brackets A and B separately (denoted as W.), place them in the SBF, and keep them moist at 37 °C.
- the degradation rate of the multi-dimensional scaffold prepared by the silk fibroin solution prepared by the prior art is as high as 21. 2%, and the silk fibroin prepared by the method is used.
- the degradation rate of the multi-dimensional scaffold prepared by the powder as a raw material does not increase significantly with the lapse of time, only 9.4% after 7W.
- the matrix scaffold material prepared by the prior art silk fibroin is not stable, and the stability of the matrix scaffold material prepared by the method of the present invention is remarkably improved.
- Example 5 Comparative experiment, the effect of the silk fibroin prepared by the method of the present invention and the matrix scaffold prepared by using the silk fibroin prepared by the prior art as a raw material on cell proliferation ability
- the 1% to 5% silk fibroin solution prepared by the present invention is the same as the step 1) of the first embodiment.
- Cross-linking scaffolds A and B were prepared using the silk fibroin liquid prepared in 1) after 2W and the silk fibroin liquid prepared in 2), respectively, in the same manner as in step 3) of Example 1.
- the A scaffold is a matrix scaffold material prepared from silk fibroin prepared according to the prior art
- the B scaffold is a matrix scaffold prepared by using the silk fibroin material prepared by the method of the present invention as a raw material. Shelf material.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/774,086 US20160206780A1 (en) | 2014-08-15 | 2014-08-15 | Matrix Scaffold for Three-Dimensional Cell Cultivation, Methods of Construction Thereof and Uses Thereof |
CN201480012266.6A CN105431179A (zh) | 2014-08-15 | 2014-08-15 | 一种用于细胞三维培养的基质支架及其构建方法和应用 |
PCT/CN2014/000771 WO2016023140A1 (zh) | 2014-08-15 | 2014-08-15 | 一种用于细胞三维培养的基质支架及其构建方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2014/000771 WO2016023140A1 (zh) | 2014-08-15 | 2014-08-15 | 一种用于细胞三维培养的基质支架及其构建方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016023140A1 true WO2016023140A1 (zh) | 2016-02-18 |
Family
ID=55303747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/000771 WO2016023140A1 (zh) | 2014-08-15 | 2014-08-15 | 一种用于细胞三维培养的基质支架及其构建方法和应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20160206780A1 (zh) |
CN (1) | CN105431179A (zh) |
WO (1) | WO2016023140A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105963790A (zh) * | 2016-05-05 | 2016-09-28 | 苏州大学 | 一种复合凝胶三维肿瘤模型支架的制备方法 |
US11840732B2 (en) | 2016-11-07 | 2023-12-12 | Iscaff Pharma Ab | Diagnostic methods |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109402059A (zh) * | 2017-09-18 | 2019-03-01 | 武汉原生原代生物医药科技有限公司 | 体外用生物膜及其制备方法和用途 |
CN109402047A (zh) * | 2017-09-18 | 2019-03-01 | 武汉原生原代生物医药科技有限公司 | 促组织粘附和生长生物粘合剂及其制备方法和用途 |
CN112899215A (zh) * | 2017-11-30 | 2021-06-04 | 山西加乐医疗科技有限责任公司 | 一种细胞支架及其制备方法 |
CN108841776B (zh) * | 2018-06-13 | 2022-05-10 | 河海大学常州校区 | 一种成分可调控的3d凝胶的制备方法及应用 |
CA3113528A1 (en) | 2018-09-21 | 2020-03-26 | Aufbau Medical Innovations Limited | Compositions and methods for glaucoma |
CN110066418B (zh) * | 2019-04-16 | 2021-08-31 | 苏州大学 | 一种活性丝素多孔材料或活性丝素膜及其制备方法 |
EP4017537A4 (en) * | 2019-08-20 | 2023-08-16 | Evolved by Nature, Inc. | SILK PERSONAL CARE COMPOSITIONS |
CN113956506B (zh) * | 2020-07-03 | 2023-07-21 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种双网络水凝胶及其制备方法与应用 |
CN112354011B (zh) * | 2020-10-12 | 2022-10-14 | 华南师范大学 | 一种肝组织工程支架及其制备方法 |
WO2022246342A1 (en) | 2021-05-21 | 2022-11-24 | Cambridge Crops, Inc. d/b/a Mori | Systems and methods for manufacturing a silk fibroin solution and powders containing silk fibroin |
CN113201222B (zh) * | 2021-05-24 | 2022-08-19 | 中国科学院西北高原生物研究所 | 一种牦牛皮胶/pmve-ma复合材料及其制备方法和用途 |
CN113929934A (zh) * | 2021-07-09 | 2022-01-14 | 泸州国之荣耀酒业有限公司 | 抗降解性明胶微球、人工肝模型及其构建方法与应用 |
US11864569B2 (en) | 2021-08-16 | 2024-01-09 | Cambridge Crops, Inc. | Systems and methods for improving the performance of cereal using a silk fibroin solution and powders containing silk fibroin |
CN113634048B (zh) * | 2021-09-10 | 2022-10-14 | 武汉纺织大学 | 天然蚕丝微纳米纤维复合多孔材料及其应用 |
CN114984313B (zh) * | 2022-04-26 | 2023-06-20 | 江苏省中医药研究院(江苏省中西医结合医院) | 一种提高丝素蛋白支架压电效应的方法 |
CN114874975B (zh) * | 2022-05-09 | 2024-04-19 | 中山大学附属第七医院(深圳) | 一种利用弹性蛋白水凝胶培养类器官的方法 |
CN115607726B (zh) * | 2022-09-29 | 2023-12-22 | 重庆中医药学院 | 一种大黄炭-壳聚糖-丝素蛋白复合材料及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103418029A (zh) * | 2013-08-29 | 2013-12-04 | 中国人民解放军军事医学科学院卫生装备研究所 | 一种丝素/壳聚糖复合多孔支架的制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101445971A (zh) * | 2008-12-19 | 2009-06-03 | 东华大学 | 仿生细胞外基质丝素蛋白/壳聚糖复合纳米纤维的制备方法 |
US9334473B2 (en) * | 2012-08-17 | 2016-05-10 | Jelena Vukasinovic | Three dimensional cell culture compositions and methods of use |
CN103436985A (zh) * | 2013-07-22 | 2013-12-11 | 苏州三和开泰花线织造有限公司 | 一种丝素蛋白/壳聚糖共混纳米纤维的制备方法 |
CN103993422B (zh) * | 2014-04-23 | 2017-03-15 | 东华大学 | 一种再生丝素蛋白/壳聚糖衍生物共混纤维毡及其制备方法 |
-
2014
- 2014-08-15 WO PCT/CN2014/000771 patent/WO2016023140A1/zh active Application Filing
- 2014-08-15 CN CN201480012266.6A patent/CN105431179A/zh active Pending
- 2014-08-15 US US14/774,086 patent/US20160206780A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103418029A (zh) * | 2013-08-29 | 2013-12-04 | 中国人民解放军军事医学科学院卫生装备研究所 | 一种丝素/壳聚糖复合多孔支架的制备方法 |
Non-Patent Citations (2)
Title |
---|
HU , ZHIWEI: "Preparation of liver-Specific Silk Fibroin-based Macroporous Microcarrier Crosslinked by EDC/NHS", CHINA MASTER'S THESES FULL-TEXT DATABASE, vol. 05, 15 May 2012 (2012-05-15), pages E080 - 41 * |
SILVA, S.S. ET AL.: "Novel Genipin-Cross-Linked Chitosan/Silk Fibroin Sponges for Cartilage Engineering Strategies", BIOMACROMOLECULES, vol. 9, no. 10, 25 September 2008 (2008-09-25), pages 2764 - 2774 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105963790A (zh) * | 2016-05-05 | 2016-09-28 | 苏州大学 | 一种复合凝胶三维肿瘤模型支架的制备方法 |
US11840732B2 (en) | 2016-11-07 | 2023-12-12 | Iscaff Pharma Ab | Diagnostic methods |
Also Published As
Publication number | Publication date |
---|---|
US20160206780A1 (en) | 2016-07-21 |
CN105431179A (zh) | 2016-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016023140A1 (zh) | 一种用于细胞三维培养的基质支架及其构建方法和应用 | |
Razavi et al. | Three‐dimensional cryogels for biomedical applications | |
CN103877617B (zh) | 可注射蚕丝素蛋白-海藻酸盐双交联水凝胶及其制备方法和使用方法 | |
CN103951831B (zh) | 丝胶蛋白水凝胶的制备方法及其应用 | |
Chopra et al. | Fabrication of poly (vinyl alcohol)-Carrageenan scaffolds for cryopreservation: Effect of composition on cell viability | |
JP6581650B2 (ja) | 温度感応性グリコールキトサン誘導体を利用したスフェロイド形成用培養容器及びそれを利用したスフェロイドの形成方法 | |
CN104342405A (zh) | 一种肿瘤微环境的体外构建方法及其在药敏筛选中的应用 | |
CN112972760A (zh) | 一种负载内皮细胞外基质的3d打印骨缺损修复支架及其制备方法 | |
WO2021068743A1 (zh) | 一种自支撑丝素蛋白导管支架的成型方法 | |
Gan et al. | GelMA/κ-carrageenan double-network hydrogels with superior mechanics and biocompatibility | |
Ghaffarinovin et al. | Repair of rat cranial bone defect by using amniotic fluid-derived mesenchymal stem cells in polycaprolactone fibrous scaffolds and platelet-rich plasma | |
Sang et al. | Photo-crosslinked hydrogels for tissue engineering of corneal epithelium | |
Li et al. | Magnetic liquid metal scaffold with dynamically tunable stiffness for bone tissue engineering | |
CN107638590A (zh) | 一种壳聚糖基梯度仿生复合支架材料及其构建方法 | |
KR101383527B1 (ko) | 합성 고분자, 폴리사카라이드 및 단백질을 포함하는 크라이오젤 스캐폴드 및 상기 스캐폴드를 이용한 조직 재생방법 | |
CN102350009A (zh) | 复合型骨基质明胶聚乳酸多孔生物活性材料的制备方法 | |
CN112111162B (zh) | 可快速固化的双网络水凝胶及其制备方法与应用 | |
CN105031724B (zh) | 一种组织工程软骨支架及其制备方法 | |
Lu et al. | Growth of fibroblast and vascular smooth muscle cells in fibroin/collagen scaffold | |
CN108084466A (zh) | 一种基于蛋清和甲基丙烯酸衍生化聚合物的复合膜及其在培养干细胞方面的应用 | |
CN204840394U (zh) | 一种具有趋化功能的生物活性支架的制备和应用 | |
CN211445769U (zh) | 一种用于构建体外肿瘤模型的3d支架 | |
CN108478864A (zh) | 复合纤维支架 | |
CN102989038B (zh) | 可递送内皮抑制激素的胶原基复合角膜替代物的制备方法和应用 | |
Chen et al. | Sandwich-like scaffold for effective hemostasis and anti-adhesion in cardiac injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480012266.6 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14774086 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14899600 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14899600 Country of ref document: EP Kind code of ref document: A1 |